These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20812236)

  • 41. Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.
    Sun W; Roland KL; Kuang X; Branger CG; Curtiss R
    Infect Immun; 2010 Mar; 78(3):1304-13. PubMed ID: 20086087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
    Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague.
    Zvi A; Rotem S; Zauberman A; Elia U; Aftalion M; Bar-Haim E; Mamroud E; Cohen O
    Vaccine; 2017 Oct; 35(44):5995-6006. PubMed ID: 28606812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.
    Tiner BL; Sha J; Ponnusamy D; Baze WB; Fitts EC; Popov VL; van Lier CJ; Erova TE; Chopra AK
    Clin Vaccine Immunol; 2015 Dec; 22(12):1255-68. PubMed ID: 26446423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.
    Tao P; Mahalingam M; Kirtley ML; van Lier CJ; Sha J; Yeager LA; Chopra AK; Rao VB
    PLoS Pathog; 2013; 9(7):e1003495. PubMed ID: 23853602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plague vaccines and the molecular basis of immunity against Yersinia pestis.
    Quenee LE; Schneewind O
    Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen.
    Liu WT; Hsu HL; Liang CC; Chuang CC; Lin HC; Liu YT
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):58-69. PubMed ID: 17640293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen.
    Chiuchiolo MJ; Boyer JL; Krause A; Senina S; Hackett NR; Crystal RG
    J Infect Dis; 2006 Nov; 194(9):1249-57. PubMed ID: 17041851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.
    Quenee LE; Ciletti NA; Elli D; Hermanas TM; Schneewind O
    Vaccine; 2011 Sep; 29(38):6572-83. PubMed ID: 21763383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.
    Philipovskiy AV; Cowan C; Wulff-Strobel CR; Burnett SH; Kerschen EJ; Cohen DA; Kaplan AM; Straley SC
    Infect Immun; 2005 Mar; 73(3):1532-42. PubMed ID: 15731051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platform technology to deliver prophylactic molecules orally: an example using the Class A select agent Yersinia pestis.
    del Rio B; Fuente JL; Neves V; Dattwyler R; Seegers JF; Gomes-Solecki M
    Vaccine; 2010 Sep; 28(41):6714-22. PubMed ID: 20699130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
    Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
    Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.
    Philipovskiy AV; Smiley ST
    Infect Immun; 2007 Feb; 75(2):878-85. PubMed ID: 17118978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.
    Chichester JA; Musiychuk K; Farrance CE; Mett V; Lyons J; Mett V; Yusibov V
    Vaccine; 2009 May; 27(25-26):3471-4. PubMed ID: 19200825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell-mediated protection against pulmonary Yersinia pestis infection.
    Parent MA; Berggren KN; Kummer LW; Wilhelm LB; Szaba FM; Mullarky IK; Smiley ST
    Infect Immun; 2005 Nov; 73(11):7304-10. PubMed ID: 16239527
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cell-mediated immune response to epitopic MAP (multiple antigen peptide) construct of LcrV antigen of Yersinia pestis in murine model.
    Shreewastav RK; Ali R; Uppada JB; Rao DN
    Cell Immunol; 2012; 278(1-2):55-62. PubMed ID: 23121976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.
    Kumar D; Kirimanjeswara G; Metzger DW
    Clin Vaccine Immunol; 2011 Nov; 18(11):1925-35. PubMed ID: 21880856
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.
    Cornelius CA; Quenee LE; Overheim KA; Koster F; Brasel TL; Elli D; Ciletti NA; Schneewind O
    Infect Immun; 2008 Dec; 76(12):5588-97. PubMed ID: 18794281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.